摘要
1型糖尿病(type 1 diabetes mellitus,T1DM)是与多基因遗传相关的自身免疫性慢性代谢性疾病,可导致视网膜病变、肾病、神经病变和足部溃疡等严重并发症。胰岛素替代疗法是目前治疗T1DM的一线治疗方案,但不足以减轻T1DM相关的自身免疫损伤或促进胰岛的再生。胰腺移植或胰岛移植及使用抗T细胞抗体疗法也存在各种问题。细胞替代疗法尤其是间充质干细胞(mesenchymal stem cells,MSCs)治疗为T1DM提供了新的思路并在临床治疗中效果突显。本研究将MSCs治疗T1DM的可能机制及研究进展作一综述。
Type 1 diabetes mellitus(TIDM)is an autoimmune chronic metabolic disease associated with multiple genes,which can lead to serious complications such as diabetic retinopathy,kidney disease,neuropathy and foot ulcers.Insulin replacement therapy is currently the first-line treatment for T1DM,but it is not enough to reduce the autoimmune damage associated with T1DM or to promote islet regeneration.Pancreas transplantation or islet transplantation and the use of anti-T cell antibody therapy also present problems.Cell replacement therapy,especially mesenchymal stem cells(MSCs)therapy provides a new idea for T1DM and shows certain therapeutic effect in clinical treatment.In this paper,the possible mechanism and research progress of MSCs in the treatment of T1DM are briefly reviewed.
作者
谢俊豪
金百翰
刘婷婷
霍翠兰
黄勤
XIE Junhao;JIN Baihan;LIU Tingting;HUO Cuilan;HUANG Qin.(Department of Endocrinology,Shanghai Changhai Hospital,the First Affiliated Hospital of Navy Military Medical University, Shanghai 200433,China)
出处
《西北国防医学杂志》
CAS
2020年第12期727-734,共8页
Medical Journal of National Defending Forces in Northwest China
基金
国家自然科学基金资助项目(81471038,81272665)。
关键词
1型糖尿病
间充质干细胞
免疫调节
细胞因子
细胞替代疗法
type 1 diabetes mellitus
mesenchymal stem cells
immune regulation
cytokines
cell replacement therapy
